Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + S-1 in advanced gastroesophageal adenocarcinoma
NCT05403242Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in gastroesophageal adenocarcinoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Dose-Limiting Toxicity at 1 year and Objective Response Rate at 1 year. Started Sep 2022; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05403242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403242.